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Abstract: Background: Previous locoregional treatment could a↵ect the response to nivolumab in
platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
The aim of this study is to evaluate the impact of the clinicopathological characteristics and previous
treatment in predicting early progression to nivolumab in a real-world population. Methods: This is
an observational, multicenter retrospective/prospective study including patients (pts) with platinum
refractory R/M HNSCC who received nivolumab 240 mg every 2 weeks from October 2018 to October
2019. We analyzed the association between previous treatment, clinicopathological characteristics,
and early progression (within 3 months). Results: Data from 61 pts were reviewed. Median age was
67 years (30–82). Forty-two pts (69%) received previous locoregional treatment. Early progression
to nivolumab occurred in 36 pts (59%), while clinical benefit (stable disease and partial response)
was achieved in 25 pts (41%). Early progression to nivolumab was significantly associated to
previous locoregional treatment both at univariate and multivariate analysis (p = 0.005 and p = 0.048,
respectively). Conclusion: nivolumab in R/M HNSCC is burdened with a high early progression
rate. Previous wide neck dissection and high dose radiotherapy may compromise the e cacy of
nivolumab, distorting the anatomy of the local lymphatic system and hindering the priming of
immune response.
Keywords: squamous cell carcinoma; head and neck cancer; immunotherapy; nivolumab; locoregional
treatment
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1. Introduction
Head and neck cancer represents the sixth most common type of neoplasia worldwide with
650,000 new cases and around 330,000 deaths each year [1]. The vast majority (more than 90%) of head
and neck cancer are squamous cell carcinoma arising from various subsites of the upper aerodigestive
tract. These cancers are strongly associated to specific risk factors such as tobacco and alcohol intake
and human papilloma virus (HPV) infection, the latter defining a distinct disease entity [2]. In the
pre-immunotherapy era, the diagnosis of unresectable recurrent and/or metastatic head and neck
squamous cell carcinoma (R/M HNSCC) was linked to an invariably poor prognosis with an expected
survival of less than 1 year [3]. Indeed, treatment options in platinum refractory disease included
monochemotherapy with taxanes and methotrexate, though none of these drugs showed a clear benefit
in term of overall survival (OS) [4]. The advent of immune checkpoint inhibitors (ICIs), a class of
drugs able to modulate immune suppressive pathways in order to prime an anticancer immunity, has
remarkably changed the management of R/M HNSCC. In the CheckMate 141 trial [5], nivolumab,
an anti-programmed death-1 (PD-1) antibody, showed a 30% reduction in the risk of death with an
objective response rate of 13.3% versus 5.8% in chemotherapy arm. Following the results from this
phase III study, nivolumab was approved, becoming the standard of care in platinum refractory disease.
Past reports on immunotherapy in non-small cell lung cancer (NSCLC) and melanoma
suggested a possible association between clinicopathological characteristics, previous treatment,
and outcomes [6–10].
To date, only a single retrospective study evaluated the e cacy and safety of nivolumab
in R/M HNSCC, showing a significant correlation between immune-related adverse events and
survival [11]. However, easily-available clinical factors, such as sex, Eastern Cooperative Oncology
Group performance status (ECOG PS), and metastatic site have shown to predict outcomes among
patients with solid tumors treated with checkpoint inhibitors [12,13].
Nevertheless, the integration of immunotherapy with other treatment, including surgery,
chemotherapy, or radiotherapy should be still further investigated and previous treatment could have
a relevant impact on the immune response.
It was shown in a preclinical study [14] that primary tumor resection was associated with a
decrease in tumor antigen presentation and T cell activity, but, at the same time, the removal of a
chronic antigen exposure allows the di↵erentiation of CD8 T cell in antitumor memory T cell. Moreover,
surgery could enhance the immune response inducing the release of the antigenic load from the
primary tumor. Otherwise, the di↵erentiation of these tumor-specific CD8+ T cells into memory cells
occurs in the sentinel lymph node and its surgical removal is associated with a negative outcome.
Unfortunately, in HNSCC, bilateral radical neck dissection is often performed, potentially/theoretically
jeopardizing the antitumor immune response.
In addition, previous chemotherapy may modify the sensitivity to immunotherapy. Some
preclinical studies have shown that a cisplatin-based regimen enhances the T cell activation, proliferation,
and their cytotoxic activity, inhibiting the immunosuppressive pathways [15].
Moreover, low dose of chemotherapy, such as gemcitabine or cyclofosfamide, seems to decrease
regulatory T cell (Treg) in the tumor microenvironment. These data suggest a synergistic e↵ect of
chemotherapy and immunotherapy in the treatment of solid tumors [16].
Furthermore, also radiotherapy could have an immune-modulatory e↵ect even though the right
dose and schedule, able to induce immunogenic death, has not been established yet, but it could be
very di↵erent from the radiation plan actually used in the treatment of HNSCC [17,18].
Therefore, we conducted a retrospective multicenter study to evaluate the e cacy and safety of
nivolumab in a real-world patient population with R/M HNSCC, particularly focusing on the impact of
previous locoregional treatments and clinicopathological characteristics on response to immunotherapy.
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2. Materials and Methods
2.1. Patients
This is an observational, multicenter, retrospective/prospective study, including patients with
platinum refractory R/M HNSCC, judged eligible for immunotherapy with nivolumab from October
2018 to October 2019. The follow-up period was from October 2018 to January 2020.
Patients were clinically staged with contrast enhanced computed tomography (CT) scan and
magnetic resonance imaging (MRI) defining baseline disease setting. Tumor tissue biopsy was
performed and the diagnosis was histologically confirmed.
Data including age, sex, body mass index (BMI), ECOG PS, comorbidities, history of tobacco
smoking and alcohol abuse, primary tumor sites, previous locoregional treatment, previous
chemotherapy and total platinum dose received, and histology were retrospectively collected. Inclusion
criteria were: platinum refractory R/M HNSCC, treated with platinum-based chemotherapy (last
platinum administration less than 6 months before), adequate liver, renal, and hematologic basal
function, PS  2, no other concomitant or previous malignant disease.
Patients who had PS > 2, a primary non-squamous histology or patients with autoimmune disease
were not included in the analysis. All patients provided a written informed consent, and the protocol
approval of Local Ethics Committee was obtained [CE 5618].
2.2. Treatment and Assessments
Nivolumab was administered according to the standard schedule: 240 mg intravenously at
2-weeks interval until disease progression or inacceptable toxicities.
Treatment toxicity was assessed every 2 weeks, according to the National Cancer Institute-Common
Terminology Criteria for Adverse Events version 4.0 (CTCAE version 4.03, 2010). Imaging assessment
with contrast enhanced CT and/or MRI was performed after 6 cycles or before in case of evident clinical
disease progression. Clinical benefit (CB), which reflected the proportion of patients with complete
response (CR), stable disease (SD), or partial response (PR), was assessed according to immune Response
Evaluation Criteria in Solid Tumours (i-RECIST) [19]. Patients experiencing disease progression (PD)
within three months from the beginning of nivolumab were defined as early progressors. Progression
free survival (PFS) was defined as the time in months from the start of immunotherapy until the
occurrence of progression or death or the date of last follow up. OS was the time in months from the
start of immunotherapy to the date of death or last follow up.
2.3. Statistical Analysis
In the descriptive analysis, quantitative variables were described as median and range, while
qualitative variables were reported as number and percentage. The association between each
clinicopathological characteristic and early PD was evaluated using the univariate and multivariable
logistic regression model. Statistical significance was set at p < 0.05. All analyses were performed
using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
A total of 61 patients with platinum-refractory R/M HNSCC, who received nivolumab at six Italian
centers, were included in this study. Their clinic-pathological characteristics are reported in Table 1.
Median age was 67 years (range, 30–82 years), and 50 patients were male (82%). Baseline ECOG PS,
evaluated before the start of nivolumab, was 0, 1, and 2 in 11 (18%), 34 (55.7%), and 16 (26.2%) patients,
respectively. The primary tumor site was the oropharynx in 14 patients (23%), the hypopharynx in
8 patients (13.1%), the larynx in 19 patients (31.1%), the oral cavity in 14 patients (23%), and other
subsite in 6 patients (9.8%). Histological type was squamous cell carcinoma in all the patients with a
tumor grade G2 and G3 in 9 and 33 patients, respectively. Grading was missing in 19 biopsies (31.2%).
HPV status was negative in 11 patients and positive in 2 patients with oropharyngeal cancer. At the
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baseline imaging evaluation with contrast enhanced CT, 11 patients (18%) had exclusively recurrent
disease without distant metastasis and 50 patients (82%) had 1 or more metastatic site.
Previous treatment is shown in Table 1. Overall, 42 patients (69%) received a locoregional
treatment including surgery and/or radiotherapy; in particular, 9 patients (14.7%) received surgery,
9 patients (14.7%) received chemoradiotherapy, 24 patients (39.3%) both surgery and chemoradiotherapy.
Standard first line platinum-based chemotherapy, according to the phase III EXTREME trial [20], was
administered in 53 patients (87%). Overall, 27 patients (44%) received carboplatin-based chemotherapy
and underwent disease progression within 6 months from the last carboplatin dose, while 28 patients
(46%) received cisplatin-based chemotherapy and underwent disease progression within 6 months
from the last cisplatin dose.
Table 1. Baseline clinicopathological characteristics.
Characteristic All Patients N 61 (%)
Age (years)
Median Age (range) 67 (30–82)
Gender
Male 50 (82)
Female 11 (18)
Baseline PS 1 before nivolumab
0 11 (18)
1 34(55.7)
2 16 (26.2)
Risk factors
Smoking history 32 (52.5)
Alcohol abuse 17 (27.9)
Tumor Location
Oral cavity 14 (23)
Oropharynx 14 (23)
Hypopharynx 8 (13.1)
Larynx 19(31.1)
Other 6 (9.8)
Histology
Squamous Cell Carcinoma 61 (100)
Grading
2 9 (14.8)
3 33 (54)
Missing 19 (31.2)
HPV 2
Positive 2 (3.3)
Negative 11 (18)
Not reported 48 (78.7)
Recurrent Disease Metastatic site
11 (18)
50 (82)
Previous locoregional treatment 42 (69)
Surgery 9 (14.7)
Chemoradiotherapy 9 (14.7)
Surgery and Chemoradiotherapy 24 (39.3)
First line platinum-based chemotherapy 53 (87)
Previous Carboplatin 27 (44)
Previous Cisplatin 28 (46)
Unknown 6 (10)
1 PS: performance status; 2 HPV: human papilloma virus.
Clinical benefit was achieved in 25 patients (39%); in particular 6 patients (10%) had partial
response and 19 patients (31%) a stable disease. Overall, early progression occurred in 36 patients
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(59%). Among the patients who experienced disease progression, 30 patients (83%) vs. 6 (17%) patients
received previous locoregional treatment as shown in Figure 1.
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Figure 1. Association between response to immunotherapy and previous locoregional treatment.
SD: stable disease; RP: partial response; PD: progressive disease.
No high grade G3–G4 toxicities were reported. For all patients, median PFS and OS was 3 months
(1–11 months) and 4 months (2–11 months), respectively; 30 patients (49%) were alive at the last
follow-up visit.
A possible association between early progression, clinicopathological characteristics, and previous
treatment was analyzed as it is shown in Table 2. At univariate analysis, early progression to
Nivolumab was significantly associated to previous locoregional treatment (p = 0.005) and the
predictive role of previous locoregional treatment was confirmed at the multivariate analysis (p = 0.048).
No significant association was found between early progression and each type of previous locoregional
treatment (single strategy with surgery or definitive chemoradiotherapy versus both surgery and
chemoradiotherapy, p = 0.075 versus p = 0.083 using the multivariate analysis, respectively). Baseline
disease staging (exclusively recurrent vs. metastatic disease) was not included in the analysis (Table 2)
because among the patients with only recurrent disease, only one did not experience early progression,
and this would lead to estimation problems.
Table 2. Correlation between clinicopathological factors and early progression during nivolumab.
Univariate Analysis Multivariate Analysis
Characteristic OR 1 (95% CI 2) p OR (95% CI) p
Sex
female vs. male 3.83 (0.75–19.56) 0.106 4.82 (0.62–37.50) 0.133
Age 0.99 (0.94–1.04) 0.580 0.94 (0.87–1.02) 0.151
Alcohol history 1.39 (0.44–4.44)
yes vs. not 0.575 1.26 (0.26–7.96) 0.775
Smoking
Yes vs. not 0.36 (0.12–1.11) 0.075 0.32 (0.07–1.49) 0.147
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Table 2. Cont.
Univariate Analysis Multivariate Analysis
Subsite
Oropharynx 1.31 (0.32–5.43) 0.711 2.38 (0.31–18.18) 0.403
Hypopharynx 0.73 (0.14–3.82) 0.707 0.60 (0.07–4.89) 0.635
Oral cavity 1.82 (0.42–7.94) 0.427 1.42 (0.22–9.02) 0.713
Larynx 1.00 (1.00–1.00) 1.00 (1.00–1.00) 0.382
Others 0.36 (0.05–2.50) 0.303 0.27 (0.01–5.03)
Locoregional treatment
yes vs. not 5.42 (1.67–17.56) 0.005 4 5.41 (1.02–28.74) 0.048 5
Platinum-CT 3
Cisplatin 0.42 (0.14–1.28) 0.127 0.31 (0.08–1.25) 0.099
Carboplatin 1.00 (1.00–1.00) 1.00 (1.00–1.00)
Unknown 0.42 (0.07–2.55) 0.347 0.30 (0.02–4.38) 0.378
1 OR: odds ratio. 2 CI: confidential interval. 3 CT: chemotherapy. 4,5 Statistical significance was set at p < 0.05.
4. Discussion
In our study, previous locoregional treatments, including surgery and/or chemoradiotherapy,
seem to be significantly associated with a high risk of early progression in R/M HNSCC patients treated
with nivolumab. Despite nivolumab being e↵ective and safe, the early progression rate was remarkably
high. Consequently, there is an urgent need to understand how to decrease the high progression risk
and improve the e↵ectiveness of immunotherapy identifying the possible clinicopathological and/or
anamnestic factors predicting response or resistance to nivolumab. Patients with locally advanced
HNSCC often received complex multimodal treatment including wide neck dissection, responsible
for the major distortion of the local lymphatic system, associated with high dose chemoradiotherapy,
representing a possible cause of damage on the activity and vitality of local immune system cells.
Although the multimodal treatment is associated with an improvement in local disease control and
a relevant reduction in local recurrence, it could cause, in the long term, an irreversible damage on
the ability of the local immune system to trigger a protective immune response against the disease
recurrence. In vitro and in vivo studies showed that the blockade of PD-1 or PD-L1 promotes antitumor
activity. The link between inhibitory immune checkpoint PD-1, often expressed on T lymphocytes, and
this ligand programmed death ligand-1 (PD-L1), primes an inhibitory signal, blocking the e↵ector and
cytotoxic function of T lymphocytes. Indeed, PD1-deficient mice often developed autoimmune disease,
while inhibition of PD-1/PD-L1 interaction lead to tumor regression in mice [21,22]. Moreover, the
antibody mediating PD-1/PD-L1 pathway blockade promotes to an increase in e↵ector antigen-specific
T-cell count and modulates cytokines secretion in vitro and in murine models [23,24] Further recent
preclinical studies have shown that surgery and radiotherapy can positively influence the e↵ect of
immunotherapy, including anti PD-1 agents, by acting as in situ vaccines, although several points have
not been clarified: the right timing of immunotherapy administration, the right radiotherapy dose and
fractionation, and the role of lymph nodes dissection. Conversely, the imbalance between all these
elements could lead to a negative and immunosuppressive e↵ect [14,25–27].
Primary tumor surgical resection can be associated with an immunosuppressive e↵ect critically
relevant in promoting escape of occult tumor cells and metastatic spread [28]. Indeed, surgery induces
the release of several cytokines, chemokines, and growth factor involved in the wound healing process.
At the same time, these factors promote the expansion of Tregs, myeloid-derived suppressor cells
(MDSC) and macrophages M2 resulting in the impairment of NK cells activity, decreasing T cell
proliferation, and increasing PD-L1 expression. All these events are peculiar to the immunosuppressive
postoperative phase which can constitute an important therapeutic window in which immunotherapy
could represent a promising opportunity [29,30]. At the same time, surgery can contribute to the
development of anti-tumor memory cells, but this event is strictly dependent on the presence of the
sentinel lymph node, that, if removed, can be associated with a negative e↵ect on the development
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of the immune response [14]. In fact, while lymph nodes have a central role in immune response
induction, the systemic e↵ect of their dissection is still uncertain, resulting both in enhancement and
disempowerment of the immune response in the gut system and head–neck region, respectively [31].
Additionally, radiation therapy could enhance the immunosuppressive e↵ect deriving from surgery and,
contemporarily, trigger a systemic immune response through the radiation-induced immunological cell
death [32]. Indeed, radiotherapy can act as an in situ vaccine in patient with irradiated tumor, through
the induction of anti-tumor T-cell response. However, the trigger of systemic immune response is
strictly dependent on the dose and fraction used in the radiation therapy schedule and the cancer cell
lines [33]. The high dose of radiotherapy applied in the curative management of HNSCC could not
allow the development of anticancer immune response, but, instead, it could compromise, through
the tissue damage, the activity of immune system cells and, like surgery, disrupt the anatomy of
draining lymph nodes station. Traditional fractionated radiation is locally immunosuppressive, because
lymphocytes are sensitive to radiation doses and are cleared rapidly from the radiation field [34].
The e↵ects of surgery and radiotherapy on immune system may explain the statistically significant
association between previous locoregional treatment and early progression, as it was shown at the
multivariate analysis in our study.
In this study, the activity of nivolumab in R/M HNSCC was in line with results of the pivotal phase
III trial [5]: in particular, response rate was 13.3% in CheckMate 141 vs. 10% of partial response in our
study group. Nevertheless, our disappointing results about OS can be explained by the short follow-up
period and by the high rate of early progressions. Moreover, in the CheckMate 141, G3–G4 toxicities rate
was 13.1%, while no relevant toxicities were reported in our study. Consequently, nivolumab was shown
to be safe also in a real-world population with unfavorable clinical characteristics. Indeed, in our group
of patients, baseline ECOG PS was 1 and 2 in 55.7% and 26.2% of patients, respectively, highlighting the
important frailty of patients in this setting, often heavily pre-treated and with symptomatic aggressive
disease. Moreover, most of patients presented with a high disease burden at diagnosis, with 82% of
them having more than one metastatic site. All these negative clinical characteristics justify, at least in
part, the poor results obtained in terms of survival. A retrospective study [11], including 100 patients
with R/M HNSCC treated with nivolumab, showed good results with a disease control rate of 49% and
a median OS of 9.6 months, although the study population was heterogeneous in terms of primary
disease subsite and histotype. The present study has some limitations to be acknowledged. This is a
retrospective multicenter study with a short follow up and a relatively small sample size, thereby with
potential for inherent biases. Therefore, a longer follow-up window and more patients are required to
perform a reliable survival analysis.
Using a multivariate analysis, previous locoregional treatments, including surgery and/or
chemoradiotherapy were confirmed to be the only independent predictive factor for early PD.
This evidence suggests that immunotherapy could probably give the best advantage in other disease
settings and/or combined with curative treatment modality, when neck anatomy is still inviolate.
Moreover, in locally pre-treated patients (with surgery and/or radiotherapy) experiencing R/M HNSCC,
immunotherapy may be less e↵ective in disease control for induced immune system impairment.
5. Conclusions
Radical surgery with the demolition of the complex lymphatic network of the neck associated
with adjuvant high dose radio-chemotherapy or primary radio-chemotherapy, carried out for reducing
local recurrence and improve disease control, radically modify the anatomy of the local lymphatic
system, hindering the priming of immune response (Figure 2).
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Figure 2. Locoregional treatment and immunity cycle. Locoregional treatment could block the
immunity cycle at di↵erent level. Primary tumor resection induces a reduction in tumor antigen
presentation, T cell activity, and, at the same time, the development of anti-tumor specific memory T
cell which is definitively compromised by local lymph nodes dissection. The first postoperative phase
is characterized by the increase of cytokines of wound healing, PD-L1 expression, myeloid-derived
suppressor cells (MDSC), macrophages M2, and Treg. Similarly, radiotherapy promotes the release of
cancer antigen through the induction of immunogenic cell death, increasing the antitumor T cell response
and cross antigen presentation. Contemporarily, radiotherapy could promote an immunosuppressive
status through the increase of local MDSC, PD-L1 expression, Treg, and macrophages M2. Healing
occurs if all neoplastic cells have been radically removed after the intensive multimodal treatment and
if micrometastatic disease is completely eradicated. However, head and neck second malignancies
could occurr for impaired immunosurveillance. Recurrent disease with a primary induced resistance
to immunotherapy is the result of an incomplete and ine↵ective first immune response.
The e↵ects of a previous aggressive, multimodal primary treatment on the immune system can
mutilate the potential of the immune system, compromising the e cacy of nivolumab in R/M setting
and may explain the association between previous locoregional treatment and high early progression
rate, expression of primary resistance to ICIs treatment, as it was shown at the multivariate analysis in
our study.
In conclusion, in the future, it will be necessary to further individualize therapeutic strategies
based on molecular biomarkers, clinic-pathological characteristics, and previous therapeutic history,
which can lead in immune system impairment, and integrate immunotherapy with standard treatment
such as surgery, chemotherapy, and radiotherapy in order to improve results in term of response rate
and survival.
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